ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE
CAPSULE; ORAL
>A> TREXIX
>A> WRAESER PHARMS LLC 320.5MG;30MG;16MG A204785 001 Nov 26, 2014 Nov NEWA

AMIFOSTINE
INJECTABLE; INJECTION
ETHYOL
>A> @ CLINIGEN HLTHCARE 375MG/VIAL N020221 002 Sep 10, 1999 Nov CAHN
>A> AP + 500MG/VIAL N020221 001 Dec 08, 1995 Nov CAHN
>D> @ MEDIMMUNE 375MG/VIAL N020221 002 Sep 10, 1999 Nov CAHN
>D> AP + 500MG/VIAL N020221 001 Dec 08, 1995 Nov CAHN

AMMONIA N-13
INJECTABLE; INTRAVENOUS
AMMONIA N 13
>A> AP MIPS CRF 30mCi-300mCi/8ML (3.75–37.5mCi/ML) A204535 001 Nov 20, 2014 Nov NEWA

ANASTROZOLE
TABLET; ORAL
ANASTROZOLE
>A> AB CIPLA LTD 1MG A091164 001 Jun 28, 2010 Nov CAHN
>D> AB THREE RIVERS PHARMS 1MG A091164 001 Jun 28, 2010 Nov CAHN

BENZOYL PEROXIDE; CLINDAMYCN PHOSPHATE
GEL; TOPICAL
ACANYA
>D> + DOW PHARM 2.5%;1.2% N050819 001 Oct 23, 2008 Nov CPOT
>A> + 2.5%; EQ 1.2% BASE N050819 001 Oct 23, 2008 Nov CPOT
>A> ONEXTON
>D> DOW PHARM 3.75%; EQ 1.2% BASE N050819 002 Nov 24, 2014 Nov NEWA

BINATOPROST
SOLUTION/DROPS; TOPICAL
BINATOPROST
>A> AT APOTEX INC 0.03% A201894 001 Dec 01, 2014 Nov NEWA
>A> LATISSE
>D> + ALLERGAN 0.03% N022369 001 Dec 24, 2008 Nov CFTG
>A> AT + 0.03% N022369 001 Dec 24, 2008 Nov CFTG

BRIMONIDINE TARTRATE
SOLUTION/DROPS; OPHTHALMIC
BRIMONIDINE TARTRATE
>A> AT INDOCO REMEDIES 0.2% A091691 001 Nov 18, 2014 Nov NEWA

BUDESONIDE
AEROSOL, FOAM; RECTAL
UCERIS
>D> + SALIX PHARMS INC 2MG N205613 001 Oct 07, 2014 Nov CPOT
>A> + 2MG/ACTION  N205613 001 Oct 07, 2014 Nov CPOT

BUTOCONAZOLE NITRATE
CREAM; VAGINAL
GYNAZOLE-1
>A> @ ELAN PHARMA INTL LTD 2% N019881 001 Feb 07, 1997 Nov CAHN
>D> @ LUMARA HEALTH INC 2% N019881 001 Feb 07, 1997 Nov CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE
SOLUTION; ORAL
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE maleate AND PSEUDOEPHEDRINE HYDROCHLORIDE
>A> AA TRIS PHARMA INC 4MG/5ML;5MG/5ML; 60MG/5ML A203838 001 Nov 26, 2014 Nov NEWA
### CLINDAMYCIN PHOSPHATE
**Cream; Vaginal**

<table>
<thead>
<tr>
<th>Deletions</th>
<th>Additions</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLINDESS</td>
<td></td>
</tr>
<tr>
<td>+ ELAN PHARMA INTL LTD</td>
<td>EQ 2% BASE N050793 001 Nov 30, 2004 Nov CAHN</td>
</tr>
<tr>
<td>+ LUMARA HEALTH INC</td>
<td>EQ 2% BASE N050793 001 Nov 30, 2004 Nov CAHN</td>
</tr>
</tbody>
</table>

### DANAPAROID SODIUM
**Injectable; Injection**

<table>
<thead>
<tr>
<th>Deletions</th>
<th>Additions</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORGANAN</td>
<td></td>
</tr>
<tr>
<td>@ AGI</td>
<td>750 UNITS/0.6ML N020430 001 Dec 24, 1996 Nov CAHN</td>
</tr>
<tr>
<td>@ ORGANON USA INC</td>
<td>750 UNITS/0.6ML N020430 001 Dec 24, 1996 Nov CAHN</td>
</tr>
</tbody>
</table>

### DEXMEDETOMIDINE HYDROCHLORIDE
**Injectable; Injection**

<table>
<thead>
<tr>
<th>Deletions</th>
<th>Additions</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEXMEDETOMIDINE HYDROCHLORIDE</td>
<td></td>
</tr>
<tr>
<td>AP AKORN INC</td>
<td>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A202585 001 Nov 24, 2014 Nov NEWA</td>
</tr>
</tbody>
</table>

### DIAZEPAM
**Gel; Rectal**

<table>
<thead>
<tr>
<th>Deletions</th>
<th>Additions</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIASTAT</td>
<td></td>
</tr>
<tr>
<td>@ VALENT</td>
<td>2.5MG/0.5ML (5MG/ML) N020648 001 Jul 29, 1997 Nov CAHN</td>
</tr>
<tr>
<td>@</td>
<td>5MG/ML (5MG/ML) N020648 002 Jul 29, 1997 Nov CAHN</td>
</tr>
<tr>
<td>@</td>
<td>10MG/2ML (5MG/ML) N020648 003 Jul 29, 1997 Nov CAHN</td>
</tr>
<tr>
<td>@</td>
<td>15MG/3ML (5MG/ML) N020648 004 Jul 29, 1997 Nov CAHN</td>
</tr>
<tr>
<td>@</td>
<td>20MG/4ML (5MG/ML) N020648 005 Jul 29, 1997 Nov CAHN</td>
</tr>
<tr>
<td>@ VALENT PHARMS NORTH</td>
<td>2.5MG/0.5ML (5MG/ML) N020648 001 Jul 29, 1997 Nov CAHN</td>
</tr>
<tr>
<td>@</td>
<td>5MG/ML (5MG/ML) N020648 002 Jul 29, 1997 Nov CAHN</td>
</tr>
<tr>
<td>@</td>
<td>10MG/2ML (5MG/ML) N020648 003 Jul 29, 1997 Nov CAHN</td>
</tr>
<tr>
<td>@</td>
<td>15MG/3ML (5MG/ML) N020648 004 Jul 29, 1997 Nov CAHN</td>
</tr>
<tr>
<td>@</td>
<td>20MG/4ML (5MG/ML) N020648 005 Jul 29, 1997 Nov CAHN</td>
</tr>
<tr>
<td>@ DIASTAT ACUDIAL</td>
<td>10MG/2ML (5MG/ML) N020648 007 Sep 15, 2005 Nov CAHN</td>
</tr>
<tr>
<td>+ VALENT</td>
<td></td>
</tr>
<tr>
<td>+ VALENT PHARMS NORTH</td>
<td>10MG/2ML (5MG/ML) N020648 007 Sep 15, 2005 Nov CAHN</td>
</tr>
<tr>
<td>+</td>
<td>20MG/4ML (5MG/ML) N020648 006 Sep 15, 2005 Nov CAHN</td>
</tr>
</tbody>
</table>

### DICLOFENAC SODIUM
**Solution; Topical**

<table>
<thead>
<tr>
<th>Deletions</th>
<th>Additions</th>
</tr>
</thead>
<tbody>
<tr>
<td>DICLOFENAC SODIUM</td>
<td></td>
</tr>
<tr>
<td>AT PADDOCK LLC</td>
<td>1.5% A202393 001 Nov 24, 2014 Nov NEWA</td>
</tr>
<tr>
<td>AT TARO</td>
<td>1.5% A203818 001 Nov 26, 2014 Nov NEWA</td>
</tr>
<tr>
<td>AT WATSON LABS INC</td>
<td>1.5% A202852 001 Nov 24, 2014 Nov NEWA</td>
</tr>
</tbody>
</table>

### DOXYCYCLINE HYCLATE
**Tablet; Oral**

<table>
<thead>
<tr>
<th>Deletions</th>
<th>Additions</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTICLATE</td>
<td></td>
</tr>
<tr>
<td>AQUA PHARMS LLC</td>
<td>EQ 150MG BASE N205931 002 Jul 25, 2014 Nov CRLD</td>
</tr>
<tr>
<td>+</td>
<td>EQ 150MG BASE N205931 002 Jul 25, 2014 Nov CRLD</td>
</tr>
</tbody>
</table>

### DROSPIRENONE; ETHINYL ESTRADIOL
**Tablet; Oral-28**

<table>
<thead>
<tr>
<th>Deletions</th>
<th>Additions</th>
</tr>
</thead>
<tbody>
<tr>
<td>YAELA</td>
<td></td>
</tr>
<tr>
<td>AB NOVAST LABS LTD</td>
<td>3MG;0.03MG A202015 001 Nov 19, 2014 Nov NEWA</td>
</tr>
</tbody>
</table>

### EPIRUBICIN HYDROCHLORIDE
**Injectable; Injection**

<table>
<thead>
<tr>
<th>Deletions</th>
<th>Additions</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPIRUBICIN HYDROCHLORIDE</td>
<td></td>
</tr>
<tr>
<td>AP EBEWE PHARMA</td>
<td>50MG/25ML (2MG/ML) A065339 001 Dec 22, 2009 Nov DISC</td>
</tr>
<tr>
<td>@</td>
<td>50MG/25ML (2MG/ML) A065339 001 Dec 22, 2009 Nov DISC</td>
</tr>
<tr>
<td>AP</td>
<td>200MG/100ML (2MG/ML) A065339 002 Dec 22, 2009 Nov DISC</td>
</tr>
<tr>
<td>@</td>
<td>200MG/100ML (2MG/ML) A065339 002 Dec 22, 2009 Nov DISC</td>
</tr>
</tbody>
</table>
ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

ESTRADIOL
SPRAY; TRANSDERMAL

> A> + ELAN PHARMA INTL LTD 1.53MG/Spray N 022014 001 Jul 27, 2007 Nov CAHN

> D> + LUMARA HEALTH INC 1.53MG/Spray N 022014 001 Jul 27, 2007 Nov CAHN

TABLET; ORAL

ESTRADIOL

> D> @ AAI PHARMA INC 0.5MG A 040138 001 Jan 30, 1998 Nov CAHN
> A> @ 1MG A 040138 002 Jan 30, 1998 Nov CAHN
> A> @ 2MG A 040138 003 Jan 30, 1998 Nov CAHN

> A> @ LANNETT HOLDINGS INC 0.5MG A 040138 001 Jan 30, 1998 Nov CAHN
> A> @ 1MG A 040138 002 Jan 30, 1998 Nov CAHN
> A> @ 2MG A 040138 003 Jan 30, 1998 Nov CAHN

ESTRADIOL VALERATE
INJECTABLE; INJECTION

DELESTROGEN

> D> AO + PAR STERILE PRODUCTS 10MG/ML N 009402 002 Aug 18, 1962 Nov CTEC
> A> + 10MG/ML N 009402 002 Aug 18, 1962 Nov CTEC

> D> AO SANDOZ 10MG/ML A 040628 001 Oct 04, 2007 Nov DISC
> A> @ 10MG/ML A 040628 001 Oct 04, 2007 Nov DISC
> D> AO 20MG/ML A 040628 002 Oct 04, 2007 Nov DISC
> A> @ 20MG/ML A 040628 002 Oct 04, 2007 Nov DISC
> D> AO 40MG/ML A 040628 003 Oct 04, 2007 Nov DISC
> A> @ 40MG/ML A 040628 003 Oct 04, 2007 Nov DISC

ETHINYL ESTRADIOL; LEVONORGESTREL
TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

> A> AB2 FAMY CARE LTD 0.02MG; 0.1MG A202247 001 Dec 08, 2014 Nov NEWA
> A> AB HAUPT PHARMA 0.03MG; 0.15MG A201095 001 Dec 08, 2014 Nov NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE
TABLET; ORAL

GILDESS 24 FE

> A> AB VINTAGE PHARMS 0.02MG; 1MG A090293 001 Dec 01, 2014 Nov NEWA
> A> AB BARR LABS INC 0.02MG; 1MG A090938 001 Dec 01, 2014 Nov NEWA

FELODIPINE
TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

> D> AB WICKHARDT LTD 2.5MG A091484 001 Aug 15, 2012 Nov DISC
> A> @ 2.5MG A091484 001 Aug 15, 2012 Nov DISC
> D> AB 5MG A091484 002 Aug 15, 2012 Nov DISC
> A> @ 5MG A091484 002 Aug 15, 2012 Nov DISC
> D> AB 10MG A091484 003 Aug 15, 2012 Nov DISC
> A> @ 10MG A091484 003 Aug 15, 2012 Nov DISC

FINASTERIDE
TABLET; ORAL

FINASTERIDE

> A> AB CIPLA LTD 1MG A077335 001 Nov 20, 2014 Nov NEWA

FLUCONAZOLE
TABLET; ORAL

FLUCONAZOLE

> D> BX DR REDDYS LABS INC 50MG A076658 001 Jul 29, 2004 Nov CTEC
> A> AB 50MG A076658 001 Jul 29, 2004 Nov CTEC
> D> BX 100MG A076658 002 Jul 29, 2004 Nov CTEC
> A> AB 100MG A076658 002 Jul 29, 2004 Nov CTEC
> D> BX 150MG A076658 003 Jul 29, 2004 Nov CTEC
> A> AB 150MG A076658 003 Jul 29, 2004 Nov CTEC
> D> BX 200MG A076658 004 Jul 29, 2004 Nov CTEC
> A> AB 200MG A076658 004 Jul 29, 2004 Nov CTEC
## Additions/Deletions for Prescription Drug Product List

### Guaiifenesin; Hydrocodone Bitartrate

- **Solution; Oral**
  - **Oberdon**
  - **Sovereign Pharms**
    - 200mg/5mL, 2.5mg/5mL
    - N205474 001 Nov 14, 2014 Nov NEWA

### Hydrocodone Bitartrate

- **Tablet, Extended Release; Oral**
  - **Hysingla**
  - **Purdue Pharma LP**
  - **Ap + Sovereign Pharms**
    - 20mg
    - N206627 001 Nov 20, 2014 Nov NEWA
    - 30mg
    - N206627 002 Nov 20, 2014 Nov NEWA
    - 40mg
    - N206627 003 Nov 20, 2014 Nov NEWA
    - 60mg
    - N206627 004 Nov 20, 2014 Nov NEWA
    - 80mg
    - N206627 005 Nov 20, 2014 Nov NEWA
    - 100mg
    - N206627 006 Nov 20, 2014 Nov NEWA
    - 120mg
    - N206627 007 Nov 20, 2014 Nov NEWA

### Idarubicin Hydrochloride

- **Injectable; Injection**
  - **Idarubicin Hydrochloride**
  - **Apo Sandoz**
  - **Apo + Mylan Institutional**

### Insulin Recombinant Human

- **Powder; Inhalation**
  - **Afrezza**
  - **Mannkind**
  - **Sanofi Aventis**
  - **Ab + Sanofi Aventis**
  - **Ab + Ap Mylan Institutional**

### Labetalol Hydrochloride

- **Tablet; Oral**
  - **Trandate**
  - **Ab Cnty Line Pharm**
  - **Ab + Sanofi Aventis**
  - **Ab + Teva**
  - **Ab + Hikma Maple**

### Leflunomide

- **Tablet; Oral**
  - **Leflunomide**
  - **Ab Sandoz**
  - **Ab + Mylan Institutional**
  - **Ab + Hikma Maple**
  - **Ab + Ap Mylan Institutional**
  - **Ab + Teva**

### Mercaptopurine

- **Tablet; Oral**
  - **Mercaptopurine**
  - **Ab Roxane**
  - **Ab + Purinethol**
  - **Ab + Teva**
  - **Ab + Hikma Maple**

### Methocarbamol

- **Injectable; Injection**
  - **Robaxin**
  - **Robaxin + Hikma Maple**

---

*Page 4 of 8*
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Formulation</th>
<th>Brand Name</th>
<th>Manufacturer</th>
<th>Strength</th>
<th>NDC Number</th>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>METHOTREXATE</td>
<td>SOLUTION; SUBCUTANEOUS</td>
<td>Otrexup</td>
<td>Antares Pharma Inc</td>
<td>7.5MG/0.4ML</td>
<td>N204824</td>
<td>Nov 07, 2014</td>
<td>NEWA</td>
</tr>
<tr>
<td>MYCOPHENolate MOFETIL</td>
<td>SUSPENSION; ORAL CELLCIPT</td>
<td></td>
<td></td>
<td></td>
<td>N050759</td>
<td>Oct 01, 1998</td>
<td>CFTG</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Roche Palo</td>
<td></td>
<td>200MG/ML</td>
<td>N050759</td>
<td>Oct 01, 1998</td>
<td>CFTG</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alkem Labs Ltd</td>
<td></td>
<td>200MG/ML</td>
<td>A203005</td>
<td>Nov 14, 2014</td>
<td>NEWA</td>
</tr>
<tr>
<td>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE</td>
<td>TABLET; ORAL TREVIMET</td>
<td></td>
<td></td>
<td></td>
<td>N021926</td>
<td>Apr 15, 2008</td>
<td>CAHN</td>
</tr>
<tr>
<td>PANTOPRAZOLE SODIUM</td>
<td>TABLET, DELAYED RELEASE; ORAL PANTOPRAZOLE SODIUM</td>
<td></td>
<td></td>
<td></td>
<td>A202052</td>
<td>Dec 02, 2014</td>
<td>NEWA</td>
</tr>
<tr>
<td>PARICALCITOL</td>
<td>INJECTABLE; INJECTION</td>
<td></td>
<td></td>
<td></td>
<td>N201657</td>
<td>Oct 21, 2014</td>
<td>CDFR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hospira Inc</td>
<td></td>
<td>0.002MG/ML</td>
<td>N201657</td>
<td>Oct 21, 2014</td>
<td>CDFR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.005MG/ML</td>
<td>N201657</td>
<td>Oct 21, 2014</td>
<td>CDFR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.01MG/2ML (0.005MG/ML)</td>
<td>N201657</td>
<td>Oct 21, 2014</td>
<td>CDFR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sandoz Canada Inc</td>
<td></td>
<td>0.002MG/ML</td>
<td>A091108</td>
<td>Jul 27, 2011</td>
<td>CDFR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.005MG/ML</td>
<td>A091108</td>
<td>Jul 27, 2011</td>
<td>CDFR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zemplar</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.002MG/ML</td>
<td>N020819</td>
<td>Feb 01, 2000</td>
<td>CDFR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.005MG/ML</td>
<td>N020819</td>
<td>Apr 17, 1998</td>
<td>CDFR</td>
</tr>
<tr>
<td>PHENIXYBENZAMINE HYDROCHLORIDE</td>
<td>CAPSULE; ORAL DIBENZYLNE</td>
<td></td>
<td></td>
<td></td>
<td>N008708</td>
<td>Jan 26, 1953</td>
<td>CAHN</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10MG</td>
<td>N008708</td>
<td>Jan 26, 1953</td>
<td>CAHN</td>
</tr>
<tr>
<td>PHENTERMINE HYDROCHLORIDE</td>
<td>CAPSULE; ORAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A205019</td>
<td>Dec 05, 2014</td>
<td>NEWA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>15MG</td>
<td>A205019</td>
<td>Dec 05, 2014</td>
<td>NEWA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30MG</td>
<td>A205019</td>
<td>Dec 05, 2014</td>
<td>NEWA</td>
</tr>
<tr>
<td>PHENYTOIN</td>
<td>TABLET, CHEWABLE; ORAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A040884</td>
<td>Nov 28, 2014</td>
<td>NEWA</td>
</tr>
</tbody>
</table>
ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

PORFIMER SODIUM
INJECTABLE, INJECTION
PHOTOFRIN

>Å> CONCORDIA LABS INC
75MG/VIAL
N020451 001 Dec 27, 1995 Nov CAHN

>D> PINNACLE BIOLOGS
75MG/VIAL
N020451 001 Dec 27, 1995 Nov CAHN

POTASSIUM CHLORIDE
TABLET, EXTENDED RELEASE, ORAL
K-TAB

>Å> BC
ABBVIE
8MEQ
N018279 002 Aug 01, 1988 Nov CMFD

>D> BC
20MEQ
N018279 003 Nov 25, 2013 Nov CRLD

>Å> BC
8MEQ
N018279 002 Aug 01, 1988 Nov CMFD

PRAMIPEXOLE DIHYDROCHLORIDE
TABLET, DELAYED RELEASE, ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

>Å> AB
SANDOZ
0.375MG
A202353 001 Dec 04, 2014 Nov NEWA

>Å> AB
0.75MG
A202353 002 Dec 04, 2014 Nov NEWA

>Å> AB
1.5MG
A202353 003 Dec 04, 2014 Nov NEWA

>Å> AB
3MG
A202353 004 Dec 04, 2014 Nov NEWA

>Å> AB
4.5MG
A202353 005 Dec 04, 2014 Nov NEWA

PREDNISOLONE SODIUM PHOSPHATE
SOLUTION, ORAL
PREDNISOLONE SODIUM PHOSPHATE

>Å> @ MEDICIS PHARMS
EQ 15MG BASE/5ML
A075250 001 Jul 12, 2002 Nov CAHN

>D> @ WE PHARMS
EQ 15MG BASE/5ML
A075250 001 Jul 12, 2002 Nov CAHN

RESERPINE
TABLET, ORAL
RESERPINE

>Å> @ CYCLE PHARMS LTD
0.1MG
N009859 001 May 04, 1955 Nov CAHN

>Å> @
0.25MG
N009859 002 May 04, 1955 Nov CAHN

>D> @ ROXANE
0.1MG
N009859 001 May 04, 1955 Nov CAHN

>D> @
0.25MG
N009859 002 May 04, 1955 Nov CAHN

SELEGILINE HYDROCHLORIDE
CAPSULE, ORAL
SELEGILINE HYDROCHLORIDE

>D> @ AAIPHARMA LLC
5MG
A075145 001 Sep 15, 2003 Nov CAHN

>A> @ LANNETT HOLDINGS INC
5MG
A075145 001 Sep 15, 2003 Nov CAHN

SILDENAFIL CITRATE
TABLET, ORAL
SILDENAFIL CITRATE

>Å> AB
HETERO LABS LTD V
EQ 20MG BASE
A203623 001 Nov 26, 2014 Nov NEWA

SIMVASTATIN
TABLET, ORAL
SIMVASTATIN

>Å> AB
ACCORD HLTHCARE
5MG
A078155 005 Apr 05, 2013 Nov NEWA

SODIUM FLUORIDE F-18
INJECTABLE, INTRAVENOUS
SODIUM FLUORIDE F-18

>Å> AP
NCM USA BRONX LLC
10-200mCi/ML
A204513 001 Nov 28, 2014 Nov NEWA

>A> THE FEINSTEIN INST
20-600mCi/ML
A204328 001 Nov 19, 2014 Nov NEWA

SODIUM IODIDE I-131
CAPSULE, ORAL
SODIUM IODIDE I-131

>Å> JUBILANT DRAXIMAGE
0.009-0.1mCi
N021305 006 May 19, 2005 Nov CPOT

>D> 9-100mCi
N021305 006 May 19, 2005 Nov CPOT
ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST

SODIUM POLYSTYRENE SULFONATE
 POWDER; ORAL, RECTAL
 SODIUM POLYSTYRENE SULFONATE
 >A> NUVO PHARM INC 15GM/BOT A204071 002 Nov 28, 2014 Nov NEWA
 >A> AA 454GM/BOT A204071 001 Nov 28, 2014 Nov NEWA

TESTOSTERONE
 FILM, EXTENDED RELEASE; TRANSDERMAL
 ANDRODERM
 >A> + ACTAVIS LABS UT INC 2MG/24HR N020489 003 Oct 20, 2011 Nov CAHN
 >A> @ 2.5MG/24HR N020489 001 Sep 29, 1995 Nov CAHN
 >A> + 4MG/24HR N020489 004 Oct 20, 2011 Nov CAHN
 >A> @ 5MG/24HR N020489 002 May 02, 1997 Nov CAHN
 >D> + WATSON LABS 2MG/24HR N020489 003 Oct 20, 2011 Nov CAHN
 >D> @ 2.5MG/24HR N020489 001 Sep 29, 1995 Nov CAHN
 >D> + 4MG/24HR N020489 004 Oct 20, 2011 Nov CAHN
 >D> @ 5MG/24HR N020489 002 May 02, 1997 Nov CAHN

GEL, METERED; TRANSDERMAL
 VOGELXO
 >D> UPSHER SMITH 12.5MG/1.25GM ACTUATION N204399 003 Jun 04, 2014 Nov CTEC
 >A> BX 12.5MG/1.25GM ACTUATION N204399 003 Jun 04, 2014 Nov CTEC

TOPOTECAN HYDROCHLORIDE
 INJECTABLE; INJECTION
 TOPOTECAN HYDROCHLORIDE
 >A> AP Cipla Ltd EQ 4MG BASE/VIAL A091199 001 Dec 01, 2010 Nov CAHN
 >D> AP THREE RIVERS PHARMS EQ 4MG BASE/VIAL A091199 001 Dec 01, 2010 Nov CAHN

VINORELBINE TARTRATE
 INJECTABLE; INJECTION
 VINORELBINE TARTRATE
 >D> AP EBEWE PHARMA EQ 10MG BASE/ML A078408 001 Feb 13, 2008 Nov DISC
 >A> @ EQ 10MG BASE/ML A078408 001 Feb 13, 2008 Nov DISC

ZOLEDRONIC ACID
 INJECTABLE; IV (INFUSION)
 ZOLEDRONIC ACID
 >A> AP SAGENT PHARMS EQ 4MG BASE/5ML A091493 001 Nov 24, 2014 Nov NEWA

ZOLMITRIPTAN
 TABLET; ORAL
 ZOLMITRIPTAN
 >A> AB JUBILANT GENERICS 2.5MG A202279 001 Nov 20, 2014 Nov NEWA
 >A> AB 5MG A202279 002 Nov 20, 2014 Nov NEWA
FEXOFENADINE HYDROCHLORIDE

> A> CHILDREN’S FEXOFENADINE HYDROCHLORIDE ALLERGY
> A> ACTAVIS MID ATLANTIC 30MG/5ML A203330 001 Nov 18, 2014 Nov NEWA

> A> CHILDREN’S FEXOFENADINE HYDROCHLORIDE HIVES
> A> ACTAVIS MID ATLANTIC 30MG/5ML A203330 002 Nov 18, 2014 Nov NEWA

FEXOFENADINE HYDROCHLORIDE TABLET; ORAL

> A> CHILDREN’S FEXOFENADINE HYDROCHLORIDE ALLERGY
> A> AUROLIFE PHARMA LLC 30MG A202039 001 Nov 19, 2014 Nov NEWA

> A> FEXOFENADINE HYDROCHLORIDE HIVES
> A> AUROLIFE PHARMA LLC 60MG A202039 002 Nov 19, 2014 Nov NEWA

> A> 180MG A202039 003 Nov 19, 2014 Nov NEWA

FEXOFENADINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL

> A> FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
> A> DR REDDYS LABS LTD 60MG; 120MG A076667 001 Nov 18, 2014 Nov NEWA

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL A-D

> A> + JOHNSON AND JOHNSON 1% N020310 001 Oct 10, 1997 Nov CAHN

> D> + MCNEIL CONS 1% N020310 001 Oct 10, 1997 Nov CAHN

NICOTINE POLACRILEX

GUM, CHEWING; Buccal

NICOTINE POLACRILEX

> A> ACTAVIS LABS NY INC EQ 2MG BASE A076569 001 Jul 29, 2004 Nov CAHN

> A> EQ 2MG BASE A078699 001 Dec 29, 2008 Nov CAHN

> A> EQ 2MG BASE A079216 001 Jul 29, 2004 Nov CAHN

> A> EQ 4MG BASE A076569 002 Jul 29, 2004 Nov CAHN

> A> EQ 4MG BASE A078697 001 Dec 29, 2008 Nov CAHN

> D> WATSON LABS EQ 2MG BASE A076569 001 Jul 29, 2004 Nov CAHN

> D> EQ 2MG BASE A078699 001 Dec 29, 2008 Nov CAHN

> D> EQ 2MG BASE A079216 001 Jul 29, 2004 Nov CAHN

> D> EQ 4MG BASE A076569 002 Jul 29, 2004 Nov CAHN

> D> EQ 4MG BASE A078697 001 Dec 29, 2008 Nov CAHN

CURRENT MONTH ADDS/DELETES LIST NOTE:

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>.

The change code description:

NEWA New drug product approval usually in the supplement month.

CAHN Applicant holder firm name has changed.

CAIN Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR Change. Dosage Form; Route of Administration.

CFTG Change. A first time generic for the innovator product. A TE Code is added.

CNFD Change. The product is moved from the Discontinued Section due to a change in marketing status.

CMS1 Change. Miscellaneous addition to list.

CMS2 Change. Miscellaneous deletion from list.

CPOT Change. Potency amount/unit.

CRLD Change. Reference Listed Drug.

CTEC Change. Therapeutic Equivalence Code.

CTNA Change. Trade Name.

DISC Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.